These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35928266)

  • 1. Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques.
    Gatto GJ; Krovi A; Li L; Massud I; Holder A; Gary J; Mills P; Mitchell J; Luecke E; Demkovich ZR; Heneine W; García-Lerma JG; Marzinke MA; Brand RM; Dobard CW; Johnson LM; Van Der Straten A
    Front Pharmacol; 2022; 13():923954. PubMed ID: 35928266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
    Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
    Su JT; Simpson SM; Sung S; Tfaily EB; Veazey R; Marzinke M; Qiu J; Watrous D; Widanapathirana L; Pearson E; Peet MM; Karunakaran D; Grasperge B; Dobek G; Cain CM; Hope T; Kiser PF
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP).
    Johnson LM; Krovi SA; Li L; Girouard N; Demkovich ZR; Myers D; Creelman B; van der Straten A
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31277461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Johnson LM; Krovi SA; Demkovich ZR; van der Straten A
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33167509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
    Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
    Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
    Makarova N; Singletary T; Peet MM; Mitchell J; Holder A; Dinh C; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Smith JM; Doncel GF
    EBioMedicine; 2022 Dec; 86():104338. PubMed ID: 36343572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
    Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
    J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
    Zane D; Roller S; Shelton J; Singh R; Jain R; Wang Y; Yang B; Felx M; Alessi T; Feldman PL
    Microbiol Spectr; 2021 Sep; 9(1):e0033921. PubMed ID: 34190595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
    Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
    Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
    Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
    EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
    Pons-Faudoa FP; Di Trani N; Capuani S; Hernandez N; Wood AM; Nehete B; Niles J; Shelton KA; Kezar S; Bushman LR; Chua CYX; Ittmann MM; Anderson PL; Nehete PN; Arduino RC; Nichols JE; Grattoni A
    J Control Release; 2023 Jun; 358():116-127. PubMed ID: 37120032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Areson C; van der Straten A; Johnson LM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates.
    Pons-Faudoa FP; Sizovs A; Shelton KA; Momin Z; Niles JA; Bushman LR; Xu J; Chua CYX; Nichols JE; Demaria S; Ittmann MM; Hawkins T; Rooney JF; Marzinke MA; Kimata JT; Anderson PL; Nehete PN; Arduino RC; Ferrari M; Sastry KJ; Grattoni A
    Adv Ther (Weinh); 2021 Mar; 4(3):. PubMed ID: 33997267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection.
    Massud I; Nishiura K; Ruone S; Holder A; Dinh C; Lipscomb J; Mitchell J; Khalil GM; Heneine W; Garcia-Lerma JG; Dobard CW
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
    J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
    Schlesinger E; Johengen D; Luecke E; Rothrock G; McGowan I; van der Straten A; Desai T
    Pharm Res; 2016 Jul; 33(7):1649-56. PubMed ID: 26975357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
    Massud I; Krovi A; Nishiura K; Ruone S; Li L; Holder A; Gary J; Mills P; Mitchell J; Khalil G; Pan Y; Luecke E; Gatto G; Heneine W; García-Lerma JG; Johnson L; van der Straten A; Dobard C
    J Antimicrob Chemother; 2022 Oct; 77(11):2964-2971. PubMed ID: 35913838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.